Advanced Oncotherapy #AVO receives first part of Yantai distribution agreement payment
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the Company’s announcement of 3 April 2018, the Company has received from Yantai Cipu, through its affiliated entity Liquid Harmony, £6.5 million as the first payment relating to the Distribution Agreement announced on 7 December 2017. The […]
Advanced Oncotherapy (AVO) – Additional financing agreement and new appointment
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces it has made further progress in attracting personnel at the forefront of their field and additional financing. Additional Financing Advanced Oncotherapy announces, that on 12 June 2017, it has entered into a further loan agreement with Blackfinch Investment Ltd, through its […]
Advanced Oncotherapy (AVO) – Additional financing agreement
Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that on Tuesday 25 April it drew down a further £2 million as part of the 12-month convertible and redeemable loan agreement announced on 27 March 2017 with Blackfinch Investment Ltd, through its subsidiary Henslow Trading Limited. This […]
Advanced Oncotherapy (AVO) – Result of General Meeting
Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that at the General Meeting held earlier today all resolutions were passed.download full film iBoy As a result the Board now has authority to utilise the Equity Financing Facility provided by Bracknor, details of which were provided in […]
Advanced Oncotherapy (AVO) – Additional financing agreement
Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that on Friday 24 March it signed an additional 12-month convertible and redeemable loan, at a conversion price of 100p, which will provide net funding of £3m, with an option to draw-down a further £2m within the next […]